Company

Prometheus Biosciences, Inc.

Prometheus Biosciences develops precision medicines for inflammatory bowel disease.

About

Prometheus Biosciences develops precision medicines for inflammatory bowel disease, including the therapeutic candidates PRA023 and PRA052. The San Diego-based company raised USD 190 mn in its March 2021 IPO and USD 500 mn in a December 2022 private placement. Merck & Co., Inc. agreed to acquire it for USD 10.8 bn in April 2023; it is at the Series C stage.

1Funding rounds

7Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in